Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001129928-16-000013
Filing Date
2016-03-24
Accepted
2016-03-24 16:51:58
Documents
17
Period of Report
2015-12-31

Document Format Files

Seq Description Document Type Size
1 2015 20-F oncyf2015-20f.htm 20-F 1708816
2 AMENDMENT - THOMPSON ex433thompson.htm EX-4.33 16218
3 AMENDMENT - LOOK ex434look.htm EX-4.34 16211
4 AMENDMENT - COFFEY ex435coffey.htm EX-4.35 16188
5 AMENDMENT - TUCHMAN ex436tuchman.htm EX-4.36 19421
6 AMENDMENT - TUCHMAN ex437tuchman.htm EX-4.37 12287
7 AMENDMENT - GILL ex438gill.htm EX-4.38 12085
8 SUBSIDIARIES ex80listofsubsidiaries2015.htm EX-8.0 3838
9 CEO CERTIFICATION ex121ceocertification2015.htm EX-12.1 13527
10 CFO CERTIFICATION ex122cfocertification2015.htm EX-12.2 12624
11 CEO CERTIFICATION ex131ceocertification2015.htm EX-13.1 7094
12 CFO CERTIFICATION ex132cfocertification2015.htm EX-13.2 5933
13 2015 MD&A ex151-2015mda.htm EX-15.1 465629
14 EY CONSENT ex152eyconsentletter2015.htm EX-15.2 4811
15 image1a01.jpg GRAPHIC 86821
16 image3a01.jpg GRAPHIC 6545
17 image4a01.jpg GRAPHIC 32654
  Complete submission text file 0001129928-16-000013.txt   2489336
Mailing Address 210 - 1167 KENSINGTON CRES NW CALGARY A0 T2N 1X7
Business Address 1167 KENSINGTON CRES NW SUITE 210 CALGARY ALBERTA CANADA T2N 1X7 ALBERTA CANADA A0 00000 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 000-31062 | Film No.: 161527725
SIC: 2834 Pharmaceutical Preparations